首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷癌症核子醫學

市場調查報告書

商品編碼

1736703

全球粒子治療市場規模（按類型、產品類型、癌症類型、區域範圍和預測）

Global Particle Therapy Market Size By Type (Proton, Heavy Ion), By Product (Cyclotrons, Synchrotrons, Synchrocyclotrons), By Cancer Type (Pediatric, Prostate, Lung, Breast), By Geographic Scope And Forecast

出版日期: 2025年05月07日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

粒子治療市場規模及預測

2024 年粒子束治療市場規模價值為 12.3694 億美元，預計到 2032 年將達到 25.7345 億美元，2026 年至 2032 年的複合年成長率為 9.59%。

粒子治療是一種體外放射治療，利用質子、中子和較重離子（例如碳）等帶電粒子來治療癌症。其最大的優點在於布拉格峰，即粒子將大部分能量沉積在特定深度時產生的布拉格峰，因此能夠精確地瞄準腫瘤，同時限制對鄰近健康組織的損害。這種精確性使得粒子治療對常規光子治療無效的癌症尤其有效。

此外，粒子治療也用於治療多種疾病，包括腦腫瘤、前列腺癌和兒童惡性腫瘤，與標準放射技術相比，其副作用更少，患者的生活品質更高。

全球粒子治療市場動態

影響粒子治療市場的關鍵市場動態是：

關鍵市場促進因素

癌症發生率上升：全球癌症發生率的上升是粒子束治療市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，癌症是全球首要死因，預計到 2020 年將導致約 1,000 萬人死亡。根據國際癌症研究機構 (IARC) 的數據，2020 年全球新增癌症病例 1,930 萬例，預計到 2040 年將增至 2,840 萬例。日益加重的癌症負擔催生了對粒子束治療等創新治療方法的需求。粒子束治療是加護治療副作用可能比傳統放射療法更少。

粒子治療技術進步：粒子治療系統的持續技術進步正在拓展其應用範圍，並刺激市場擴張。根據美國國家癌症研究所 (NCI) 的數據，2021 年美國已有 37 個粒子治療中心運作，另有多個正在建造或規劃中。根據粒子治療合作組織 (PTCOG) 的統計數據，截至 2021 年，全球整體已有 103 個粒子治療設施運作，另有 41 個正在建設中。設施數量的快速成長反映了粒子治療系統的廣泛應用和技術日益成熟。

醫療支出不斷成長：醫療支出不斷成長，尤其是在已開發國家，正在加速粒子束療法等創新癌症治療方法的普及。根據經濟合作暨發展組織(OECD) 的數據，2019 年 OECD 國家的醫療支出成長快於經濟成長，平均佔 GDP 的 8.8%。根據美國醫療保險和醫療補助服務中心 (CMS) 的數據，到 2020 年，全國醫療支出將增加 9.7%，達到 4.1 兆美元，人均醫療支出將達到 12,530 美元。醫療支出的不斷成長促使人們投資於粒子束療法等最先進治療，從而推動市場成長。

主要問題

營運成本高：建立和運作粒子治療中心需要對迴旋加速器和同步加速器等先進技術進行大量投資，這對許多醫療機構來說成本高昂。這一經濟障礙減少了可用的治療中心數量，尤其是在新興國家，限制了患者獲得這種新型醫療手段的機會，並阻礙了整體市場的成長。

醫護人員認知度有限：儘管粒子療法益處良多，但許多腫瘤科醫師和醫護人員仍未意識到其相較於傳統療法的優勢。這種認知差距導致粒子治療替代方案利用不足，患者未被轉介至更先進的治療方案。加強醫護人員的教育和培訓，對於提高粒子治療的採用率並改善癌症治療的患者預後至關重要。

主要趨勢

癌症發生率不斷上升：預計到 2022 年，全球新患者將達到 2,000 萬，對粒子束治療等先進治療方法的需求也日益成長。這一趨勢促使醫療保健專業人員使用能夠有效治療惡性腫瘤的新治療方法，同時減少對健康組織的損害，改善患者的預後和生活品質。

加大醫療基礎設施投資：包括日本和中國在內的亞太國家正在大力投資建造更多的粒子治療中心。此類基礎設施的擴建對於滿足日益成長的晚期癌症治療需求至關重要，因為這些目標人口龐大，且存在大量未滿足的需求。粒子治療可近性的改善有望加速這些地區的粒子治療普及。

Particle therapy is a type of external beam radiotherapy that uses charged particles, such as protons, neutrons, or heavier ions (such as carbon), to treat cancer. Its greatest advantage is the Bragg peak, which occurs when particles deposit the majority of their energy at a given depth, allowing for accurate tumor targeting while limiting harm to adjacent healthy tissues. This precision makes particle therapy especially useful for cancers that are resistant to traditional photon-based therapies.

Furthermore, particle therapy is used to treat a variety of diseases, including brain tumors, prostate cancer, and pediatric malignancies, with fewer side effects and a higher quality of life for patients than standard radiation techniques.

Global Particle Therapy Market Dynamics

The key market dynamics that are shaping the Particle Therapy Market include:

Key Market Drivers

Rising Cancer Incidence: The growing prevalence of cancer worldwide is a primary driver of the Particle Therapy Market. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. According to the International Agency for Research on Cancer (IARC), there were 19.3 million new cancer cases worldwide in 2020, with the number expected to climb to 28.4 million by 2040. The expanding cancer burden is generating demand for innovative treatment methods such as particle therapy, which provides focused treatment with possibly fewer side effects than conventional radiotherapy.

Technological Advancements in Particle Therapy: Continuous technological advancements in particle treatment systems are broadening their applications and fueling market expansion. According to the National Cancer Institute (NCI), 37 particle therapy centers were in operation in the United States in 2021, with several more under construction or in the planned stages. According to the Particle Therapy Co-Operative Group (PTCOG) statistics, there were 103 particle therapy facilities in operation globally as of 2021, with an additional 41 under construction. This rapid growth of facilities reflects the increasing adoption and technological maturity of particle therapy systems.

Increasing Healthcare Expenditure: Rising healthcare spending, particularly in industrialized countries, is accelerating the adoption of innovative cancer treatment methods such as particle therapy. According to the Organization for Economic Cooperation and Development (OECD), health spending in OECD countries increased faster than economic growth in 2019, accounting for 8.8% of GDP on average. According to the Centers for Medicare and Medicaid Services (CMS), national health spending increased by 9.7% to USD 4.1 Trillion in 2020, or $12,530 per person. This increased healthcare spending allows for investments in cutting-edge treatments such as particle therapy, which drives market growth.

Key Challenges:

High Operational Costs: Establishing and operating particle therapy centers necessitates significant investment in advanced technology, such as cyclotrons and synchrotrons, which are prohibitively expensive for many healthcare facilities. This financial barrier reduces the number of available treatment centers, particularly in developing countries, limiting patient access to this new medicine and impeding overall market growth.

Limited Awareness among Healthcare Providers: Despite the benefits of particle therapy, many oncologists and healthcare professionals remain unaware of its advantages over traditional treatments. This awareness gap results in the underutilization of particle therapy alternatives, as patients are not recommended for advanced therapies. Increased education and training for healthcare practitioners are critical to increasing adoption rates and improving patient outcomes in cancer treatment.

Key Trends:

Growing Prevalence of Cancer: The need for advanced treatment modalities like particle therapy is growing as the number of new cases of cancer is expected to reach 20 million worldwide in 2022. This trend is encouraging healthcare practitioners to use novel therapies that reduce damage to healthy tissues while efficiently treating malignancies, thereby improving patient outcomes and quality of life.

Increased Investment in Healthcare Infrastructure: Countries in Asia Pacific, including Japan and China, are making significant investments to develop more particle therapy centers. This infrastructure expansion is critical for supporting the growing demand for advanced cancer treatments, which is driven by a large target population and significant unmet clinical needs. Improved access to particle therapy is expected to accelerate its adoption in these regions.

Global Particle Therapy Market Regional Analysis

Here is a more detailed regional analysis of the Particle Therapy Market:

North America:

According to Verified Market Research, North America is estimated to dominate the market during the forecast period. North America, particularly the United States, has a high cancer burden, which drives the desire for sophisticated treatment options such as particle therapy. According to the American Cancer Society's Cancer Facts & Figures 2023, the United States is expected to see 1,958,310 new cancer cases and 609,820 cancer deaths in 2023. The National Cancer Institute estimates that 39.5% of men and women will be diagnosed with cancer at some point in their lives. This high incidence rate is a major driving force behind the region's adoption of novel cancer treatments such as particle therapy.

Furthermore, North America has a robust healthcare research and development ecosystem, which fosters advances in cancer treatment technology. The National Cancer Institute (NCI) states that it got $6.9 billion for cancer research in fiscal year 2022, with a significant portion of that going toward discovering and refining cancer treatment modalities. Also, the Particle Therapy Co-Operative Group (PTCOG) said that as of 2021, 37 particle treatment facilities were in operation in North America, with several more under construction or in the planning phases. This concentration of research funds and infrastructure demonstrates the region's commitment to developing particle therapy methods and treatments.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth within the market during the forecast period. The Asia-Pacific region has experienced a huge increase in cancer diagnoses, fueling demand for innovative treatment alternatives such as particle therapy. According to the World Health Organization's International Agency for Research on Cancer (IARC), the Asia-Pacific region accounted for 49.3% of all new cancer cases worldwide in 2020. According to GLOBOCAN 2020 data, there were approximately 9.5 million new cancer cases in Asia in 2020, with the number expected to rise to 14.7 million by 2040. This significant and growing cancer burden is a crucial factor in the region's adoption of novel cancer treatments like particle therapy.

Furthermore, many Asian countries are aggressively promoting the research and application of innovative medical technologies, such as particle therapy. For example, Japan, a leader in particle therapy in Asia, has received major government backing for this technique. According to the Particle Therapy Co-Operative Group (PTCOG), Japan has the most particle therapy facilities in Asia, with 20 operational as of 2021. The Japanese government has designated particle treatment as an "advanced medical technology" and is providing financial assistance for its development and deployment. Similarly, countries such as China and South Korea are rapidly growing their particle therapy capabilities, with official support.

Global Particle Therapy Market: Segmentation Analysis

The Particle Therapy Market is segmented on the basis of Type, Product, and Cancer Type.

Particle Therapy Market, By Type

Proton Therapy
Heavy Ion Therapy

Based on Type, the market is segmented into Proton Therapy and Heavy Ion Therapy. The proton therapy segment is estimated to dominate the Particle Therapy Market due to proton therapy's precision targeting capabilities, which enable the effective treatment of many malignancies while minimizing damage to adjacent healthy tissues. Its improved dose distribution and low long-term adverse effects make it especially appealing for pediatric cases and complicated cancers, resulting in widespread acceptance among healthcare providers and patients. As technology advances and treatment delivery improves, proton therapy's position as the top choice in particle therapy is projected to strengthen further.

Particle Therapy Market, By Product

Cyclotrons
Synchrotrons
Synchrocyclotrons

Based on Product, the Particle Therapy Market is segmented into Cyclotrons, Synchrotrons, and Synchrocyclotrons. The cyclotrons segment is estimated to dominate the market over the forecast period. Cyclotrons are critical components of proton therapy systems, producing and accelerating protons to provide targeted radiation to malignancies. Their broad use is driven by their efficacy in treating a variety of malignancies, including pediatric instances and complicated tumors. As healthcare facilities spend more on innovative cancer treatment technologies, the need for cyclotrons is likely to increase, strengthening their market dominance.

Particle Therapy Market, By Cancer Type

Pediatric Cancer
Prostate Cancer
Lung Cancer
Breast Cancer
Others

Based on Cancer Type, the market is divided into Pediatric Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, and Others. The pediatric cancer segment is estimated to dominate the global market due to a growing knowledge of children's unique therapeutic demands, which are particularly vulnerable to radiation. Particle therapy's precision reduces damage to surrounding healthy tissues, making it an excellent choice for treating pediatric cancers. As knowledge of the efficacy and safety of particle therapy in younger patients grows, this segment is projected to maintain its market leadership.

Key Players

The "Particle Therapy Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Accuray Incorporated, Brainlab, Elekta AB, xstrahl, Danfysik A/S, Hitachi Ltd., Mevion Medical Systems, IBA Worldwide, Panacea, and Shinva Medical Instrument Co. Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Particle Therapy Market Recent Developments
In September 2023, Siemens Healthineers AG showcased breakthrough technology at the American Society for Radiation Oncology (ASTRO) 2023 annual meeting in California, demonstrating their dedication to innovation and improved results.

1 INTRODUCTION OF GLOBAL PARTICLE THERAPY MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PARTICLE THERAPY MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL PARTICLE THERAPY MARKET, BY TYPE

5.1 Overview
5.2 Heavy Ion
5.3 Proton Therapy

6 GLOBAL PARTICLE THERAPY MARKET, BY PRODUCT

6.1 Overview
6.2 Cyclotrons
6.3 Synchrotrons
6.4 Synchrocyclotrons

7 GLOBAL PARTICLE THERAPY MARKET, BY CANCER TYPE

7.1 Overview
7.2 Pediatric Cancer
7.3 Prostate Cancer
7.4 Lung Cancer
7.5 Breast Cancer

8 GLOBAL PARTICLE THERAPY MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL PARTICLE THERAPY MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Accuray Incorporated
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Brainlab
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Elekta AB
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Xstrahl
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Danfysik A/S
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Hitachi Ltd
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Mevion Medical Systems
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 IBA Worldwide
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Panacea
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Shinva Medical Instrument Co. Ltd.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments